The 4th Annual Stem Cell Summit was held yesterday in New York. One of the chief attraction of this conference was Dr. Naughton’s presentation of preliminary results of the first human clinical evaluation of RegenicaTM.
Dr. Gail Naughton is the founder and CEO of the company Histogen which develops and markets regenerative medicine. RegenicaTM is their proprietary liquid formulation which facilitates hair regrowth.
Most interestingly the company uses newborn fibroblasts for their medicine but the fibroblasts are artificially created. They have bioreactors which imitates the conditions in which embryo thrives. No animal or human components are used.
These fibroblasts are cultured to harvest naturally secreted embryonic wnt proteins, growth factors, and other synergistic bioproducts. These wnt proteins and natural cofactors used to manufacture the formulation induce the development of new hair follicles.
The wnt proteins have been administered to the mice. The proteins have been found to initiate epidermal stem cells to create new hair follicles and also to maintain the hair inducing activity of existing follicles.
Preliminary clinical trial of RegenicaTM showed that not only the product is absolutely safe to use but also causes increase in hair thickness and volume.The trial is currently ongoing, and Histogen expects to release full results from this first clinical study in the first half of 2009.